angiotensin-mediated vasodilation involved in regulation of systemic arterial blood pressure
Definition
Target type: biologicalprocess
The process that increases the diameter of a blood vessel via the renin-angiotensin system. [GOC:pr, ISBN:0323031951, PMID:10425188]
Angiotensin II, a potent vasoconstrictor, can also trigger vasodilation in certain circumstances, contributing to the complex regulation of systemic arterial blood pressure. This vasodilatory effect of angiotensin II is mediated through the activation of the AT1 receptor, which in turn activates the production of nitric oxide (NO) by endothelial cells. NO is a potent vasodilator that relaxes smooth muscle cells in blood vessels.
The mechanism involves the following steps:
1. **Angiotensin II Binding:** Angiotensin II binds to AT1 receptors on endothelial cells lining blood vessels.
2. **Signal Transduction:** The binding of angiotensin II to AT1 receptors activates a signaling cascade involving G proteins, phospholipase C, and intracellular calcium.
3. **NO Production:** This signaling cascade triggers the production of NO by endothelial nitric oxide synthase (eNOS) within endothelial cells.
4. **Vasodilation:** NO diffuses from endothelial cells into the smooth muscle cells of blood vessels, where it activates guanylate cyclase, an enzyme that converts GTP to cGMP. cGMP is a second messenger that leads to relaxation of the smooth muscle cells, causing vasodilation.
This angiotensin II-mediated vasodilation plays a role in the regulation of blood pressure by counteracting the vasoconstrictive effects of angiotensin II. It helps maintain appropriate blood flow to different organs and tissues, ensuring proper perfusion. The balance between angiotensin II-induced vasoconstriction and vasodilation is critical for the fine-tuning of blood pressure regulation. Additionally, this process highlights the complexity of angiotensin II signaling, where the same hormone can elicit different effects depending on the specific receptor subtype activated, the location, and the cellular context.'
"
Proteins (1)
| Protein | Definition | Taxonomy |
|---|---|---|
| Type-2 angiotensin II receptor | An angiotensin II receptor 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P50052] | Homo sapiens (human) |
Compounds (29)
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| 5-iodo-2-(oxaloamino)benzoic acid | organoiodine compound | ||
| candesartan | candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension. candesartan: a nonpeptide angiotensin II receptor antagonist | benzimidazolecarboxylic acid; biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
| avapro | irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease. | azaspiro compound; biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
| losartan | losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. | biphenylyltetrazole; imidazoles | angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist |
| miconazole | 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes. Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion. | dichlorobenzene; ether; imidazoles | |
| ipsapirone | N-arylpiperazine | ||
| flesinoxan | |||
| valsartan | valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity. Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. | biphenylyltetrazole; monocarboxylic acid; monocarboxylic acid amide | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
| telmisartan | telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension. Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION. | benzimidazoles; biphenyls; carboxybiphenyl | angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic |
| bexarotene | benzoic acids; naphthalenes; retinoid | antineoplastic agent | |
| exp7711 | EXP7711: to search, use E#P7711(nm); angiotensin II receptor antagonist; structure given in first source | ||
| bibs 39 | BIBS 39: structure given in first source; angiotensin II receptor antagonist | ||
| a 81988 | A 81988: angiotensin II antagonist selective for type 1 receptors | ||
| bibs 222 | BIBS 222: structure given in first source; angiotensin II receptor antagonist | ||
| chrysamine g | chrysamine G: structure given in first source; RN refers to disodium salt | ||
| angiotensin ii | Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V). | amino acid zwitterion; angiotensin II | human metabolite |
| l 158809 | L 158809: RN & structure given in first source; angiotensin receptor antagonist | ||
| 2-(oxaloamino)benzoic acid | (oxaloamino)benzoic acid | ||
| alitretinoin | Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA. | retinoic acid | antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist |
| tak 013 | |||
| pd 123319 | PD123319 : An imidazopyridine consisting of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine having 4-(dimethylamino)-3-methylbenzyl, diphenylacetyl and carboxy and groups at positions 1, 5 and 6 respectively | imidazopyridine | angiotensin receptor antagonist; endothelin receptor antagonist; vasoconstrictor agent |
| exp 655 | |||
| saralasin | Saralasin: An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. | oligopeptide | |
| l 162313 | L 162313: a biphenylimidazole derivative; a non-peptide angiotensin agonist; no further information available 2/95 | ||
| l 163491 | L 163491: structure given in first source | ||
| nrx 194204 | IRX4204: retinoid X receptor (RXR) agonist; structure in first source | ||
| agn 194204 | AGN 194204: a retinoid X receptor ligand; structure in first source | ||
| ema401 | |||
| naluzotan | naluzotan: an antidepressant and anti-anxiety agent; structure in first source |